Cancer BiologyJournal of Medicinal ChemistryPeer-reviewed
Discovery of Novel, Potent and Orally Bioavailable SMARCA2 PROTACs with Synergistic Anti-tumor Activity in Combination with KRAS G12C Inhibitors.
Sasikumar Kotagiri, Yawen Wang, Yanyan Han…·Yonathan Lissanu
This paper discovers and characterizes potent SMARCA2 PROTACs that show anti-tumor activity and synergize with KRAS G12C inhibitors in SMARCA4 mutant lung cancer.
12 citations